Head-to-head · WeighScore
Bliv vs Luma Health Co
The verdict
Luma Health Co takes it — 75/100 to 66.3/100.
Luma Health Co grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luma Health Co is a nurse-practitioner-led virtual weight-loss and wellness clinic founded by Tiffani McKnight, FNP-C.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bliv | Luma Health Co |
|---|---|---|
| WeighScore | 66.3/100 | 75/100 |
| Grade | C | C |
| Scorecard rank | #187 | #59 |
| Semaglutide | $116/mo (as low as, varies by plan and eligibility, compounded) | $120/mo (plus a separate fee, compounded) |
| Tirzepatide | $199/mo (as low as, varies by plan and eligibility, compounded) | $180/mo (compounded) |
| Coverage | Coverage not published | 30 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #187 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- The advertised rates are 'as low as' figures footnoted 'based on plan structure and eligibility', and the plan selector sits behind the medical intake — the rate you are offered is not knowable before you hand over a medical history
- A $24.99 provider consultation fee is charged on top, and the refund policy deducts $200 for 'clinical coordination and account setup'
- The homepage advertises 'no long-term commitments or cancellation fees' while the terms require the membership fee to be paid 'in a single sum', call it non-refundable and refer to a 'Membership Term'
- The only figure smaller than the advertised rate is a $29 CareCredit/Klarna instalment, which is a financing payment rather than the price of a month of medication
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #59 · C
Strengths
- Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
- No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
- Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
- Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
- HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission
Where it loses points
- Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
- Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
- No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
- Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
- Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.